Obsidian Therapeutics presented updated data from the Phase 1 study of OBX-115, an engineered tumor-derived autologous T-cell immunotherapy, at the 2024 American Society of Clinical Oncology Annual Meeting.
OBX-115 exhibited a differentiated safety profile compared to IL2-dependent non-engineered TIL cell therapies. The therapy demonstrated a consistent efficacy profile in heavily pre-treated patients with resistant/refractory disease.
The study included data from 10 patients in the safety analysis and nine patients in the per-protocol efficacy analysis set. OBX-115 showed promising early activity without the administration of IL2.
Key findings included:
• Sustained efficacy, including objective response rates and median progression-free survival comparable to other late-line systemic therapies.
• Positive safety profile, no severe cytokine release syndrome or neurotoxicity observed.
• Potential for optimized cell therapy product, including non-surgical tumor tissue procurement and re-energizing engrafted cells.
Based on these results, Obsidian continues enrolling patients with advanced or metastatic melanoma and non-small cell lung cancer in a Phase 1/2 multicenter study. The company is exploring the potential of OBX-115 to advance the TIL cell therapy field by enabling non-surgical tumor tissue procurement and eliminating the need for IL2.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
